Stock listing
KRX:348150 KoBioLabs, Inc. (고바이오랩) 주가
Follow KoBioLabs, Inc. into a list and get an email when it puts out news.
Share price · KRX:348150
₩2,650.00 KRW +110.00 (+4.3%)
Close on Nov 20, 2026
- Day range
- ₩2,550.00 – ₩2,680.00 KRWNov 20, 2026
- Volume
- 10,906 sharesNov 20, 2026
- Market cap
- ₩51.46B KRWAt the close on Nov 20, 2026 · price × 19.42M shares outstanding
- 52-week range
- ₩2,310.00 – ₩8,730.00 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩51.48M KRWMedian day 15,252 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:348150 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩2,650.00 | +110.00 | +4.3% | ₩2,680.00 | ₩2,680.00 | ₩2,550.00 | 10,906 | |
| ₩2,540.00 | -15.00 | -0.6% | ₩2,555.00 | ₩2,595.00 | ₩2,510.00 | 5,155 | |
| ₩2,555.00 | -50.00 | -1.9% | ₩2,545.00 | ₩2,620.00 | ₩2,480.00 | 15,085 | |
| ₩2,605.00 | -85.00 | -3.2% | ₩2,750.00 | ₩2,750.00 | ₩2,540.00 | 7,488 | |
| ₩2,690.00 | +10.00 | +0.4% | ₩2,650.00 | ₩2,745.00 | ₩2,650.00 | 18,360 | |
| ₩2,680.00 | +10.00 | +0.4% | ₩2,605.00 | ₩2,680.00 | ₩2,585.00 | 4,935 | |
| ₩2,670.00 | +50.00 | +1.9% | ₩2,630.00 | ₩2,770.00 | ₩2,575.00 | 6,815 | |
| ₩2,620.00 | +85.00 | +3.4% | ₩2,550.00 | ₩2,700.00 | ₩2,500.00 | 7,609 | |
| ₩2,535.00 | -80.00 | -3.1% | ₩2,530.00 | ₩2,655.00 | ₩2,530.00 | 13,984 | |
| ₩2,615.00 | 0.00 | 0.0% | ₩2,630.00 | ₩2,630.00 | ₩2,490.00 | 19,042 | |
| ₩2,615.00 | -35.00 | -1.3% | ₩2,655.00 | ₩2,710.00 | ₩2,585.00 | 7,935 | |
| ₩2,650.00 | -5.00 | -0.2% | ₩2,585.00 | ₩2,660.00 | ₩2,530.00 | 19,076 | |
| ₩2,655.00 | -20.00 | -0.7% | ₩2,610.00 | ₩2,670.00 | ₩2,560.00 | 5,736 | |
| ₩2,675.00 | +5.00 | +0.2% | ₩2,665.00 | ₩2,720.00 | ₩2,610.00 | 5,422 | |
| ₩2,670.00 | -50.00 | -1.8% | ₩2,635.00 | ₩2,735.00 | ₩2,600.00 | 10,085 | |
| ₩2,720.00 | 0.00 | 0.0% | ₩2,780.00 | ₩2,780.00 | ₩2,600.00 | 12,126 | |
| ₩2,720.00 | -30.00 | -1.1% | ₩2,765.00 | ₩2,790.00 | ₩2,635.00 | 11,164 | |
| ₩2,750.00 | +135.00 | +5.2% | ₩2,600.00 | ₩2,750.00 | ₩2,600.00 | 18,068 | |
| ₩2,615.00 | -15.00 | -0.6% | ₩2,650.00 | ₩2,685.00 | ₩2,595.00 | 5,279 | |
| ₩2,630.00 | -95.00 | -3.5% | ₩2,700.00 | ₩2,700.00 | ₩2,600.00 | 18,704 | |
| ₩2,725.00 | -120.00 | -4.2% | ₩2,855.00 | ₩2,865.00 | ₩2,630.00 | 30,611 | |
| ₩2,845.00 | 0.00 | 0.0% | ₩2,890.00 | ₩2,890.00 | ₩2,790.00 | 12,415 | |
| ₩2,845.00 | -30.00 | -1.0% | ₩2,900.00 | ₩2,900.00 | ₩2,760.00 | 5,402 | |
| ₩2,875.00 | +65.00 | +2.3% | ₩2,760.00 | ₩2,890.00 | ₩2,755.00 | 9,941 | |
| ₩2,810.00 | +130.00 | +4.9% | ₩2,750.00 | ₩2,890.00 | ₩2,695.00 | 13,551 | |
| ₩2,680.00 | -70.00 | -2.5% | ₩2,750.00 | ₩2,750.00 | ₩2,610.00 | 20,847 | |
| ₩2,750.00 | +50.00 | +1.9% | ₩2,850.00 | ₩2,860.00 | ₩2,745.00 | 18,248 | |
| ₩2,700.00 | -130.00 | -4.6% | ₩2,830.00 | ₩2,870.00 | ₩2,680.00 | 26,879 | |
| ₩2,830.00 | -50.00 | -1.7% | ₩2,890.00 | ₩2,950.00 | ₩2,830.00 | 17,825 | |
| ₩2,880.00 | +5.00 | +0.2% | ₩2,825.00 | ₩2,975.00 | ₩2,810.00 | 15,662 | |
| ₩2,875.00 | -110.00 | -3.7% | ₩2,980.00 | ₩2,980.00 | ₩2,875.00 | 21,113 | |
| ₩2,985.00 | -5.00 | -0.2% | ₩3,000.00 | ₩3,030.00 | ₩2,960.00 | 15,348 | |
| ₩2,990.00 | -5.00 | -0.2% | ₩2,935.00 | ₩3,010.00 | ₩2,930.00 | 16,316 | |
| ₩2,995.00 | +105.00 | +3.6% | ₩2,895.00 | ₩3,000.00 | ₩2,815.00 | 38,960 | |
| ₩2,890.00 | +175.00 | +6.4% | ₩2,750.00 | ₩2,915.00 | ₩2,695.00 | 40,694 | |
| ₩2,715.00 | -10.00 | -0.4% | ₩2,740.00 | ₩2,740.00 | ₩2,655.00 | 13,165 | |
| ₩2,725.00 | +60.00 | +2.3% | ₩2,670.00 | ₩2,745.00 | ₩2,655.00 | 44,855 | |
| ₩2,665.00 | +55.00 | +2.1% | ₩2,615.00 | ₩2,690.00 | ₩2,615.00 | 18,056 | |
| ₩2,610.00 | -20.00 | -0.8% | ₩2,700.00 | ₩2,700.00 | ₩2,610.00 | 17,979 | |
| ₩2,630.00 | -100.00 | -3.7% | ₩2,675.00 | ₩2,685.00 | ₩2,595.00 | 37,610 | |
| ₩2,730.00 | 0.00 | 0.0% | ₩2,765.00 | ₩2,770.00 | ₩2,625.00 | 43,362 | |
| ₩2,730.00 | -45.00 | -1.6% | ₩2,760.00 | ₩2,760.00 | ₩2,710.00 | 8,546 | |
| ₩2,775.00 | +5.00 | +0.2% | ₩2,850.00 | ₩2,850.00 | ₩2,695.00 | 18,612 | |
| ₩2,770.00 | 0.00 | 0.0% | ₩2,770.00 | ₩2,850.00 | ₩2,710.00 | 13,121 | |
| ₩2,770.00 | -70.00 | -2.5% | ₩2,840.00 | ₩2,850.00 | ₩2,750.00 | 16,064 | |
| ₩2,840.00 | -65.00 | -2.2% | ₩2,905.00 | ₩2,905.00 | ₩2,820.00 | 5,928 | |
| ₩2,905.00 | +35.00 | +1.2% | ₩2,870.00 | ₩2,930.00 | ₩2,820.00 | 33,976 | |
| ₩2,870.00 | -5.00 | -0.2% | ₩2,875.00 | ₩2,905.00 | ₩2,825.00 | 9,173 | |
| ₩2,875.00 | -35.00 | -1.2% | ₩2,910.00 | ₩2,915.00 | ₩2,850.00 | 19,188 | |
| ₩2,910.00 | 0.00 | 0.0% | ₩2,890.00 | ₩2,950.00 | ₩2,855.00 | 9,405 | |
| ₩2,910.00 | +75.00 | +2.6% | ₩2,855.00 | ₩2,925.00 | ₩2,850.00 | 10,672 | |
| ₩2,835.00 | -140.00 | -4.7% | ₩2,970.00 | ₩2,970.00 | ₩2,795.00 | 31,787 | |
| ₩2,975.00 | -5.00 | -0.2% | ₩3,030.00 | ₩3,030.00 | ₩2,890.00 | 8,973 | |
| ₩2,980.00 | +45.00 | +1.5% | ₩2,935.00 | ₩2,985.00 | ₩2,920.00 | 15,156 | |
| ₩2,935.00 | -135.00 | -4.4% | ₩3,070.00 | ₩3,070.00 | ₩2,890.00 | 22,879 | |
| ₩3,070.00 | +100.00 | +3.4% | ₩2,970.00 | ₩3,070.00 | ₩2,905.00 | 12,978 | |
| ₩2,970.00 | -90.00 | -2.9% | ₩3,060.00 | ₩3,060.00 | ₩2,940.00 | 36,326 | |
| ₩3,060.00 | -10.00 | -0.3% | ₩3,070.00 | ₩3,115.00 | ₩3,020.00 | 42,202 | |
| ₩3,070.00 | -25.00 | -0.8% | ₩2,970.00 | ₩3,085.00 | ₩2,850.00 | 52,972 | |
| ₩3,095.00 | +95.00 | +3.2% | ₩2,945.00 | ₩3,100.00 | ₩2,945.00 | 13,959 | |
| ₩3,000.00 | -120.00 | -3.8% | ₩3,085.00 | ₩3,085.00 | ₩2,925.00 | 36,315 | |
| ₩3,120.00 | +140.00 | +4.7% | ₩3,030.00 | ₩3,215.00 | ₩3,030.00 | 11,111 |
- Ticker
- KRX:348150
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- KRX
- Currency
- KRW
KoBioLabs, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
Valuation
EV/sales 0.1× against a median of 35.0×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩9.37B KRW
- P/E
- Loss
- EV/sales
- 0.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.8×
- Gross margin
- 75.0%
- Operating margin
- −10.7%
- Net margin
- −6.4%
- Debt to equity
- 0.2×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| KoBioLabs, Inc. · KRX:348150 | US$38.47M | US$7.00M | n/a | 0.1× | n/a | 1.8× | −6.4% | 0.2× | n/a |
| Dogwood Therapeutics, Inc. · NASDAQ:DWTX | US$39.57M | US$34.74M | n/a | 347× | n/a | 0.6× | n/a | 0.0× | 0.79 |
| Herantis Pharma PLC · OMXHEX:HRTIS | US$38.69M | US$38.62M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Quratis Inc. · KRX:348080 | US$38.60M | US$29.66M | n/a | 36.2× | n/a | 1.1× | n/a | 0.0× | n/a |
| Harvard Apparatus Regenerative Technology Inc · OTC:HRGN | US$38.54M | US$36.69M | n/a | 36.5× | n/a | 73.8× | −642.0% | 0.0× | 0.09 |
| OSE Immunotherapeutics SA · EURONEXT:OSE | US$38.31M | US$52.28M | n/a | 18.2× | n/a | 1.3× | n/a | 1.3× | n/a |
| Sprint Bioscience AB · OMXSTO:SPRINT | US$37.98M | US$28.86M | 5.1× | 2.1× | 3.7× | 4.3× | 54.4% | 0.0× | n/a |
| Theralase Technologies Inc. · TSXV:TLT | US$37.89M | US$34.22M | n/a | 61.1× | n/a | 7.9× | −472.5% | 0.0× | 0.75 |
| Connect Biopharma Holdings Limited · NASDAQ:CNTB | US$37.15M | US$18.16M | n/a | 4.9× | n/a | 3.1× | n/a | 0.0× | 0.93 |
| Coiled Therapeutics PLC · LSE:COIL | US$37.13M | US$30.46M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | n/a |
| TaiRx, Inc. · TPEX:6580 | US$37.08M | US$28.62M | n/a | 33.8× | n/a | 3.3× | −793.3% | 0.0× | n/a |
| Median of the others | US$38.14M | US$32.34M | 5.1× | 35.0× | 3.7× | 3.1× | −557.3% | 0.0× | 0.77 |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 3, 2024 · After close | +1.2% |
| Q4 2023 | Mar 20, 2024 · After close | −0.3% |
| Q3 2023 | Nov 14, 2023 · After close | +3.7% |
| Q2 2023 | Aug 14, 2023 · After close | −2.7% |
| Q4 2022 | Mar 21, 2023 · After close | −1.5% |
| Q3 2022 | Nov 14, 2022 · After close | +1.8% |
| Quarter to Mar 31, 2021 | May 17, 2021 | −3.2% |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 69.3B | 68.4B | 33.1B | 11.6B | 2.89B | 4.59B | 576.5M | 64.2M |
| Cost of revenue | 18.2B | 21.5B | 9.41B | 3.58B | 984.2M | 1.95B | 288.7M | 42.7M |
| Gross profit | 51.1B | 46.8B | 23.7B | 8.02B | 1.91B | 2.64B | 287.9M | 21.5M |
| Research and development | 7.57B | 6.91B | 14.3B | 14.2B | 12.5B | 8.88B | ||
| Selling, general and administrative | 49.5B | 46.4B | 27.5B | 13.9B | 5.62B | 5.99B | 3.26B | 1.58B |
| Operating income | -9.65B | -6.44B | -18.4B | -20.3B | -16.3B | -12.3B | -7.35B | -2.35B |
| Depreciation and amortization | 2.78B | 2.51B | 1.45B | 835.7M | 167.1M | 209.9M | 118.7M | 59.6M |
| EBITDA | -6.87B | -3.93B | -17.0B | -19.5B | -16.2B | -12.1B | -7.23B | -2.29B |
| Interest expense | 512.4M | 1.16B | 1.53B | 1.68B | 152.6M | 708.1M | 0 | 0 |
| Income before tax | -6.94B | -4.18B | -14.7B | -23.0B | -16.4B | -55.1B | -44.1B | -8.38B |
| Net income | -6.33B | -5.30B | -13.9B | -21.9B | -15.4B | -55.1B | -44.1B | -8.38B |
| Earnings per share, basic | -325.97 | -273.46 | -734.03 | -1,308.07 | -863.74 | -3,548.82 | -2,858.54 | -543.75 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.59B | 5.69B | 10.0B | 10.4B | 52.7B | 40.6B | 1.28B | 3.82B |
| Short-term investments | 42.5B | 29.0B | 56.2B | 54.0B | 34.0B | 10.3B | 31.6B | 4.50B |
| Receivables | 3.93B | 3.27B | 1.86B | 701.9M | 199.2M | 2.68B | 262.2M | 45.5M |
| Inventory | 5.71B | 4.47B | 1.47B | 977.5M | 256.2M | 105.6M | 123.0M | 185.3M |
| Current assets | 59.9B | 66.7B | 75.7B | 102.5B | 98.6B | 57.8B | 34.7B | 8.90B |
| Property, plant and equipment | 31.2B | 34.9B | 20.5B | 5.79B | 383.2M | 384.5M | 318.4M | |
| Total assets | 91.3B | 102.1B | 114.6B | 123.9B | 105.3B | 58.5B | 35.3B | 9.29B |
| Accounts payable | 2.30M | 3.55M | 68.6M | |||||
| Current liabilities | 13.3B | 13.8B | 21.2B | 8.94B | 6.84B | 3.09B | 88.9B | 21.2B |
| Long-term debt | 6.43B | 8.67B | 9.17B | 11.8B | 7.63B | |||
| Total debt | 57.1M | 73.0M | ||||||
| Total liabilities | 42.0B | 64.2B | 52.8B | 46.6B | 14.7B | 3.15B | 88.9B | 21.2B |
| Shareholders' equity | 32.4B | 37.9B | 45.0B | 77.3B | 90.6B | 55.4B | -53.6B | -11.9B |
| Shares outstanding | 19.4M | 19.4M | 18.9M | 16.8M | 17.8M | 15.5M | 15.4M | 15.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -5.78B | -4.36B | -13.8B | -16.6B | -12.5B | -12.8B | -5.71B | -1.98B |
| Capital spending | -552.9M | -1.65B | -15.6B | -14.8B | -5.55B | -125.0M | -290.2M | -295.9M |
| Free cash flow | -6.34B | -6.00B | -29.4B | -28.6B | -18.9B | -13.0B | -10.9B | -2.28B |
| Cash from investing | 6.43B | 8.19B | -61.8B | -31.2B | 21.0B | -27.4B | 5.11B | |
| Cash from financing | -6.51B | 4.05B | 36.3B | 55.7B | 31.0B | 30.6B | 44.7M | |
| Share buybacks | 151.3M | 395.2M | 30.3B | 42.4B | 31.1B | 30.6B | ||
| Change in cash | -1.10B | -4.36B | -386.2M | -42.3B | 12.1B | 39.3B | -2.54B | 3.17B |
Cap table
Built by 6ix from KoBioLabs, Inc.’s releases
- Common shares
- 19,418,889
- Fully diluted
- 19,418,889
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 19,418,889 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 19,418,889 |
Log in to ask 6ix AI your own questions about KoBioLabs, Inc.